z-logo
Premium
Melatonin protects the retina from experimental nonexudative age‐related macular degeneration in mice
Author(s) -
Diéguez Hernán H.,
González Fleitas María F.,
Aranda Marcos L.,
Calanni Juan S.,
Keller Sarmiento María I.,
Chianelli Mónica S.,
Alaimo Agustina,
Sande Pablo H.,
Romeo Horacio E.,
Rosenstein Ruth E.,
Dorfman Damián
Publication year - 2020
Publication title -
journal of pineal research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 131
eISSN - 1600-079X
pISSN - 0742-3098
DOI - 10.1111/jpi.12643
Subject(s) - melatonin , retina , retinal pigment epithelium , pineal gland , macular degeneration , oxidative stress , biology , melanosome , retinal degeneration , endocrinology , medicine , melanin , ophthalmology , neuroscience , genetics
Abstract Nonexudative age‐related macular degeneration (NE‐AMD) represents the leading cause of blindness in the elderly. Currently, there are no available treatments for NE‐AMD. We have developed a NE‐AMD model induced by superior cervical ganglionectomy (SCGx) in C57BL/6J mice, which reproduces the disease hallmarks. Several lines of evidence strongly support the involvement of oxidative stress in NE‐AMD‐induced retinal pigment epithelium (RPE) and outer retina damage. Melatonin is a proven and safe antioxidant. Our aim was analysing the effect of melatonin in the RPE/outer retina damage within experimental NE‐AMD. The treatment with melatonin starting 48 h after SCGx, which had no effect on the ubiquitous choriocapillaris widening, protected visual functions and avoided Bruch´s membrane thickening, RPE melanin content, melanosome number loss, retinoid isomerohydrolase (RPE65)‐immunoreactivity decrease, and RPE and hotoreceptor ultrastructural damage induced within experimental NE‐AMD exclusively located at the central temporal (but not nasal) region. Melatonin also prevented the increase in outer retina/RPE oxidative stress markers and a decrease in mitochondrial mass at 6 weeks post‐SCGx. Moreover, when the treatment with melatonin started at 4 weeks post‐SCGx, it restored visual functions and reversed the decrease in RPE melanin content and RPE65‐immunoreactivity. These findings suggest that melatonin could become a promising safe therapeutic strategy for NE‐AMD.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here